Stoke Therapeutics, Inc. STOK Other External Program Costs — Operating Expenses

Other product segments

Similar metrics at other companies

ARQTOther program costs — R&D

$95K-92.0%

PRD

PRDOAll Other Expenses — Operating Expenses

$4.2M-9.8%

RAPPPreclinical Programs External Expenses — Research And Development Expense

$4.29M+32.1%

PTENOther — Operating costs and expenses

$2.88M-68.5%

VNOOther — Operating Costs and Expenses

$43.2M+2.1%

RRROther — Operating costs and expenses

$7.7M+6.3%

Questions, answered.

What is Stoke Therapeutics, Inc.'s other external program costs — operating expenses?

Stoke Therapeutics, Inc. (STOK) reported other external program costs — operating expenses of -$3.18M in Q1 2026.

How has Stoke Therapeutics, Inc.'s other external program costs — operating expenses changed year-over-year?

Stoke Therapeutics, Inc.'s other external program costs — operating expenses decreased by 73.8% year-over-year, from -$1.83M to -$3.18M.

What is the long-term trend for Stoke Therapeutics, Inc.'s other external program costs — operating expenses?

Over 2 years (2023 to 2025), Stoke Therapeutics, Inc.'s other external program costs — operating expenses has grown at a -5.3% compound annual growth rate (CAGR), from -$9.85M to -$8.84M.

What does other external program costs — operating expenses mean?

This metric represents the aggregate operating expenses allocated to secondary or non-core research and development programs outside of the company's primary clinical pipeline. It captures the costs associated with early-stage discovery efforts, exploratory research, or ancillary projects that do not yet meet the criteria for primary program reporting. Monitoring these costs helps investors assess the company's investment in long-term pipeline diversification and the efficiency of its secondary research initiatives.